What is the price target for EWTX stock?
18 analysts have analysed EWTX and the average price target is 38.93 USD. This implies a price increase of 27.06% is expected in the next year compared to the current price of 30.64.
NASDAQ:EWTX • US28036F1057
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EDGEWISE THERAPEUTICS INC (EWTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-17 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-03-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-27 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-11-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-25 | Goldman Sachs | Initiate | Neutral |
| 2025-08-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-30 | HC Wainwright & Co. | Initiate | Buy |
| 2025-06-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-04-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-04-03 | ScotiaBank | Downgrade | Sector Outperform -> Sector Perform |
| 2025-04-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-02 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-07 | ScotiaBank | Initiate | Sector Outperform |
| 2025-03-04 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-22 | Stifel | Initiate | Hold |
| 2024-12-17 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-11-27 | Truist Securities | Maintains | Buy -> Buy |
| 2024-11-22 | Evercore ISI Group | Initiate | Outperform |
| 2024-11-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-10-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-09-20 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-09-19 | Truist Securities | Maintains | Buy -> Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 710.36% | N/A 162.89% | N/A 128.58% | N/A 67.83% | N/A 58.84% | N/A 27.24% | ||||||||
| EBITDA YoY % growth | -9.8M | -17M -73.47% | -42.95M -152.65% | -71.29M -65.98% | -112.806M -58.24% | -156.763M -38.97% | -189.322M -20.77% | N/A -15.68% | N/A -13.99% | N/A 15.02% | N/A 177.28% | N/A 219.36% | N/A 62.96% | N/A 72.77% | N/A 2.31% | |
| EBIT YoY % growth | -9.92M | -17.19M -73.29% | -43.22M -151.43% | -71.66M -65.80% | -114.357M -59.58% | -158.832M -38.89% | -191.406M -20.51% | N/A -30.80% | N/A -13.67% | N/A 19.11% | N/A 48.91% | N/A 240.40% | N/A 166.63% | N/A 109.13% | N/A 49.22% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -0.87 | -1.27 -45.98% | -1.58 -24.41% | -1.45 8.23% | -1.63 -12.41% | N/A -31.92% | N/A -12.28% | N/A 23.59% | N/A 32.43% | N/A 156.14% | N/A 229.45% | N/A 129.87% | N/A 62.80% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.50 -15.58% | -0.51 -50.82% | -0.51 -29.90% | -0.54 -15.46% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -53.833M -18.45% | -53.648M -29.04% | -52.79M -16.54% | -55.42M -2.83% |
| EBIT Q2Q % growth | -57.832M -25.83% | -60.74M -42.55% | -58.71M -25.29% | -64.115M -14.53% |
All data in USD
18 analysts have analysed EWTX and the average price target is 38.93 USD. This implies a price increase of 27.06% is expected in the next year compared to the current price of 30.64.
EDGEWISE THERAPEUTICS INC (EWTX) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of EDGEWISE THERAPEUTICS INC (EWTX) is -0.5 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering EDGEWISE THERAPEUTICS INC (EWTX) is 18.